Immuron and US Department of Defense look to develop silver bullet for gastro infections

Biopharmaceutical company Immuron (ASX: IMC) is making significant territorial advances in its mission to develop and market a range of oral immunotherapeutics for the treatment of gut mediated pathogens.

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.